FilingReader Intelligence
Xingqi Pharmaceutical begins phase II voriconazole eye drug trial
August 12, 2025 at 08:43 AM UTC•By FilingReader AI
Xingqi Pharmaceutical has begun Phase II trials for its voriconazole ophthalmic solution to treat fungal keratitis. The randomized, multi-center trial will assess efficacy and safety while determining optimal concentrations for Phase III.
No voriconazole ophthalmic solutions for this indication have been approved by China's National Medical Products Administration.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300573•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Shenyang Xingqi Pharmaceutical publishes news
Free account required • Unsubscribe anytime